MorphoSys AG

MOR

DE0006632003

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:37:06 2024-07-16 EDT			5-day change	1st Jan Change
67.75 ^EUR	0.00%		+0.22%	+99.26%

07-15	MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	MT
07-12	Novartis Seeks Squeeze Out Approval at MorphoSys AGM	MT

MORPHOSYS : Morgan Stanley reiterates its Neutral rating

January 08, 2021 at 06:37 am

Analyst Mark Purcell from Morgan Stanley research gives the stock a Neutral rating. The target price is still set at EUR 105.

Latest news about MorphoSys AG

MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	07-15	MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM	07-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	06-26	MT
INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax	06-23	DP
MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)	06-23	CI
MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index	06-23	CI
MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX Index (Price Return)	06-23	CI
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	06-20	DP
Novartis: towards the filing of a buyout offer for MorphoSys	06-20	CF
MorphoSys Set to Delist Following Acquisition by Novartis	06-20	MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis	06-20	MT
Biotech company Morphosys will soon disappear from the stock exchange	06-20	RE
MorphoSys to Leave Deutsche Börse’s MDAX, TecDAX Indices	06-19	MT
MorphoSys AG(XTRA:MOR) dropped from S&P Global BMI Index	06-09	CI
MorphoSys AG Announces Board Changes	06-06	CI
MorphoSys AG Appoints Arkadius Pichota as Chief Executive Officer	06-06	CI
MorphoSys AG Appoints Lukas Gilgen as CFO	06-06	CI
Three newcomers to the MDax - Rational, TUI and Traton move up	06-06	RE
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	06-04	MT
SMA Solar and Morphosys are about to leave the MDax	06-03	RE
Novartis data42 AG completed the acquisition of MorphoSys AG from group of shareholders.	05-29	CI
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	05-20	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	05-17	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	05-16	MT
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15	05-16	DP

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for MorphoSys AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

67.75 EUR

Average target price

58.71 EUR

Spread / Average Target

-13.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHOSYS AG	+99.26%	2.79B
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research

MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

MORPHOSYS : Morgan Stanley reiterates its Neutral rating

Latest news about MorphoSys AG

Chart MorphoSys AG

Company Profile

Income Statement Evolution

Ratings for MorphoSys AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research